JP2017536362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536362A5 JP2017536362A5 JP2017526671A JP2017526671A JP2017536362A5 JP 2017536362 A5 JP2017536362 A5 JP 2017536362A5 JP 2017526671 A JP2017526671 A JP 2017526671A JP 2017526671 A JP2017526671 A JP 2017526671A JP 2017536362 A5 JP2017536362 A5 JP 2017536362A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- benzo
- alkyl
- nhc
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 benzo [d] isoxazolyl Chemical group 0.000 claims 75
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000016998 Conn syndrome Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004540 benzothiazol-5-yl group Chemical group S1C=NC2=C1C=CC(=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000003585 oxepinyl group Chemical group 0.000 claims 1
- 208000013846 primary aldosteronism Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086218P | 2014-12-02 | 2014-12-02 | |
| US62/086,218 | 2014-12-02 | ||
| PCT/US2015/063064 WO2016089800A1 (en) | 2014-12-02 | 2015-12-01 | Aldosterone synthase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536362A JP2017536362A (ja) | 2017-12-07 |
| JP2017536362A5 true JP2017536362A5 (enExample) | 2019-01-17 |
| JP6707084B2 JP6707084B2 (ja) | 2020-06-10 |
Family
ID=54937372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526671A Active JP6707084B2 (ja) | 2014-12-02 | 2015-12-01 | アルドステロンシンターゼ阻害薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9890171B2 (enExample) |
| EP (1) | EP3227300B1 (enExample) |
| JP (1) | JP6707084B2 (enExample) |
| WO (1) | WO2016089800A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110270295B (zh) * | 2019-07-31 | 2021-08-24 | 北京六合宁远科技有限公司 | 一种氨基取代苯并吡啶含氮杂环的制备方法 |
| CN120187713A (zh) * | 2022-11-23 | 2025-06-20 | 上海翰森生物医药科技有限公司 | 吡啶多环类化合物抑制剂、及其制备方法和应用 |
| CN121194968A (zh) * | 2023-05-12 | 2025-12-23 | 江苏德源药业股份有限公司 | 含氮杂环类化合物及其应用 |
| WO2025021062A1 (zh) * | 2023-07-21 | 2025-01-30 | 上海翰森生物医药科技有限公司 | 三并环类化合物、及其制备方法和应用 |
| TW202519227A (zh) * | 2023-11-10 | 2025-05-16 | 大陸商上海齊魯製藥研究中心有限公司 | 稠環衍生物、其製備方法及其在醫藥上的應用 |
| CN121135736A (zh) * | 2024-03-01 | 2025-12-16 | 浙江扬厉医药技术有限公司 | 吡喃并吡啶类化合物、其制备方法、药物组合物及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1899334T3 (pl) * | 2005-06-17 | 2009-04-30 | Janssen Pharmaceutica Nv | Związki naftyrydynowe |
| WO2011061168A1 (en) * | 2009-11-17 | 2011-05-26 | Novartis Ag | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| EP3587401A1 (en) * | 2011-11-30 | 2020-01-01 | F. Hoffmann-La Roche AG | New bicyclic dihydroisoquinoline-1-one derivatives |
| LT2838883T (lt) | 2012-04-17 | 2018-01-25 | F. Hoffmann-La Roche Ag | Nauji feniltetrahidroizochinolino dariniai |
| JP6067181B2 (ja) * | 2013-04-30 | 2017-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| JP6471153B2 (ja) * | 2013-10-17 | 2019-02-13 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルドステロン合成酵素阻害剤としての新規フェニルジヒドロピリジン誘導体 |
| PT3172212T (pt) * | 2014-07-24 | 2018-10-08 | Boehringer Ingelheim Int | Inibidores de aldosterona sintase |
| SG11201701850UA (en) * | 2014-10-15 | 2017-04-27 | Boehringer Ingelheim Int | Aldosterone synthase inhibitors |
-
2015
- 2015-12-01 WO PCT/US2015/063064 patent/WO2016089800A1/en not_active Ceased
- 2015-12-01 EP EP15813641.6A patent/EP3227300B1/en active Active
- 2015-12-01 US US15/532,126 patent/US9890171B2/en active Active
- 2015-12-01 JP JP2017526671A patent/JP6707084B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536362A5 (enExample) | ||
| EP3820860B1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| CN107406438B (zh) | 溴结构域的抑制剂 | |
| JP6517976B2 (ja) | 炎症性障害の治療のための化合物及びその医薬組成物 | |
| CA2915622C (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
| KR102427777B1 (ko) | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 | |
| WO2015015318A2 (en) | Novel quinazolinones as bromodomain inhibitors | |
| RU2009128739A (ru) | Производные аза-бицикло[3.1.0.]гексана в качестве антагонистов рецептора орексина | |
| JP2014526500A5 (enExample) | ||
| KR20150138858A (ko) | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| JP2015536973A (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| WO2015092634A1 (en) | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders | |
| JP2017528506A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| US9890171B2 (en) | Aldosterone synthase inhibitors | |
| JP2018503647A5 (enExample) | ||
| RU2010151143A (ru) | Замещенные хиназолины | |
| HK1251553A1 (zh) | 苯并异恶唑衍生物盐 | |
| CA3271448A1 (en) | THERAPEUTIC AGENTS TO IMPROVE EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | |
| JP2016505628A5 (enExample) | ||
| JP6586326B2 (ja) | 進行前立腺癌治療薬 | |
| TW202214585A (zh) | 經取代之異喹啉基甲基醯胺類、其類似物及使用其之方法 | |
| HK40048208B (en) | Pyridazine compounds for inhibiting nav1.8 | |
| HK40048208A (en) | Pyridazine compounds for inhibiting nav1.8 | |
| CN1201390A (zh) | 用于治疗运动障碍的5－ht3受体拮抗剂 |